Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] License Strategic Alliance and Research Agreements [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Legal Entity [Axis] Actuate Therapeutics [Member] Collaboration Agreement [Member] Sale of Stock [Axis] Reverse Stock Split and IPO [Member] Securities Purchase Agreement [Member] Pre-Funded Warrants [Member] Placement Agent Warrants [Member] Private Placement [Member] Private Placement Warrants [Member] Title and Position [Axis] Board of Directors [Member] Award Type [Axis] Restricted Stock [Member] Award Date [Axis] December 2025 [Member] April 2026 [Member] Warrant [Member] Class of Warrant or Right [Axis] Location, Statement of Income, Balance [Axis] Investment Type [Axis] US Treasury Securities [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Money Market Funds [Member] Mutual Funds Fixed Income [Member] Mutual Funds Alternative Investments [Member] Asset Class [Axis] Cash and Cash Equivalents [Member] Marketable Securities [Member] Placement Agent [Member] Investors [Member] Measurement Input Type [Axis] Measurement Input, Exercise Price [Member] Measurement Input, Expected Term [Member] Measurement Input, Option Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Dividend Rate [Member] Measurement Input, Share Price [Member] Antidilutive Securities [Axis] Private Placement Warrants and Placement Agent Warrants [Member] Share-Based Payment Arrangement, Option [Member] Segments [Axis] Single Operating Segment [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Open Medicine AI [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Listing, Par Value Per Share Statement of Financial Position [Abstract] CURRENT ASSETS Cash and cash equivalents Marketable securities Prepaid expenses & other current assets Total current assets Property and equipment, net Operating lease right-of-use assets Deferred offering costs Other assets TOTAL ASSETS CURRENT LIABILITIES Accounts payable and accrued expenses Operating lease liabilities, current Total current liabilities Warrant liability TOTAL LIABILITIES COMMITMENTS AND CONTINGENCIES (NOTE 4) STOCKHOLDERS’ (DEFICIT) EQUITY Preferred Stock (1,000,000 authorized at June 30, 2026 and December 31, 2025; $.0001 par value) (Zero shares issued and outstanding at June 30, 2026 and December 31, 2025) Common Stock (25,000,000 authorized at June 30, 2026 and December 31, 2025; $.0001 par value) (12,759,146 and 11,254,697 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively) Additional paid-in capital Accumulated other comprehensive (loss) income Accumulated deficit Total stockholders’ (deficit) equity TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY Preferred stock, shares authorized Preferred stock, par value Preferred stock, shares issued Preferred stock, shares outstanding Common stock, shares authorized Common stock, par value Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating expenses: General and administrative Research and development Total operating expenses Loss from operations Interest income Other income, net Loss on issuance of warrants Warrant issuance costs Change in fair value of warrant liability NET LOSS Net loss per share of common shares, basic Net loss per share of common shares, diluted Weighted-average number of common shares outstanding, basic Weighted-average number of common shares outstanding, diluted NET LOSS Other comprehensive loss Unrealized loss on available-for-sale securities Unrealized loss on foreign currency translation Other comprehensive loss Comprehensive loss Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Stock-based compensation Net loss Other comprehensive loss Vesting of restricted common stock issued for services Issuance of common stock in Offering, net of proceeds allocated to warrants Issuance of common stock in Offering, net of proceeds allocated to warrants, shares Issuance of restricted common stock for services Issuance of restricted common stock for services, shares Issuance of common stock upon exercise of stock options Issuance of common stock upon exercise of stock options, shares Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net loss to cash used in operating activities: Depreciation and amortization Non-cash lease adjustments Vesting of restricted common stock issued for services Stock-based compensation Write-off of deferred offering costs Accretion of discounts on available for sale debt securities, net Loss on issuance of warrants Warrant issuance costs Change in fair value of warrant liability Foreign currency remeasurement gain Realized gain on redemptions of available for sale debt securities Realized loss on redemption of equity securities Unrealized loss (gain) on equity securities Changes in assets and liabilities: Prepaid expenses and other current assets Accounts payable and accrued expenses Operating lease liabilities Other assets Net cash flows used in operating activities INVESTING ACTIVITIES Purchase of property and equipment Purchases of marketable securities Redemptions of marketable securities Net cash flows provided by investing activities FINANCING ACTIVITIES Proceeds received from Offering, net of issuance costs Proceeds received from stock option exercise Net cash flows provided by financing activities Effect of foreign exchange rates on cash CHANGE IN CASH AND CASH EQUIVALENTS FOR THE PERIOD CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS, END OF PERIOD Non-cash investing and financing activities: Offering costs in accounts payable and accrued expenses Deferred offering costs in accounts payable and accrued expenses Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Principal Activities, and Basis of Presentation Liquidity and Going Concern Accounting Policies [Abstract] Summary of Significant Accounting Policies Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Leases [Abstract] Leases Equity [Abstract] Stockholders’ Equity Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Of Warrants Fair Value of Warrants Earnings Per Share [Abstract] Loss Per Share Segment Reporting [Abstract] Segment Reporting Subsequent Events [Abstract] Subsequent Event Use of Estimates and Assumptions Foreign Currency Risks and Uncertainties Research and Development Cash and Cash Equivalents Prepaid Expenses and Other Current Assets Leases Marketable Securities Deferred Offering Costs Warrant Liability Stock-based Compensation New Accounting Pronouncements Not Yet Adopted Schedule of Research and Development Schedule of Accounts Payable and Accrued Liabilities Schedule of Balance Sheet Information Related to Leases Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases Schedule of Reconciliation of Right-of-Use Assets and lease Liabilities Schedule of Other Supplemental Information Related to Operating Leases Schedule of Lease Expense Schedule of Warrants Issued and Outstanding Schedule of Stock Option Activity Schedule of Stock-based Compensation Schedule of Assets are Measured at Fair Value on Recurring Basis Schedule of Change in Fair Value of the Warrant Liability Schedule of Fair Value Accounting of Warrant Activity Schedule of Fair Value of Warrants Schedule of Anti-dilutive Securities Outstanding Diluted Loss Per Share Schedule of Segment Reporting Information Net loss Working capital Proceeds from issuance of common stock Proceeds from issuance of cost Cash and cash equivalents Prepaid expense and other current assets Upfront payments for contractor fees, academic research studies and services, and subscriptions Prepaid annual insurance fees Interest receivable Deferred offering costs Conversion of Stock Deferred offering expenses Research and Development, Contract to Perform for Others [Table] Research and Development Arrangement, Contract to Perform for Others [Line Items] Amount Expensed for License, Strategic Alliance, and Research Agreements Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Amount accrued and payable under License, Strategic Alliance, and Research Agreements Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements CommitmentsAndContingenciesDisclosureTable [Table] Actuate stock of restricted shares Number of shares hold Common stock held by fair value Operating lease, right-of-use asset, net Current portion of operating lease liabilities 2026 (remaining six months) Less amount representing interest Present value of future minimum lease payments Less current portion of operating lease liabilities Operating lease liabilities, net of current portion Operating right-of-use assets, beginning balance Operating lease liabilities, beginning balance Operating right-of-use assets, amortizations and reductions Operating lease liabilities, amortizations and reductions Operating right-of-use assets, ending balance Operating lease liabilities, ending balance Weighted average remaining term of operating leases (in years) Weighted average discount rate of operating leases Operating lease cost Short-term lease cost Lease expense New lease payments Lessee, Operating Lease, Renewal Term Remaining lease term Cash used in operating activities associated with leases Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Warrants Issued and Outstanding Weighted average exercise price Exercisable date Expiration date Number of options outstanding, beginning balance Weighted average exercise price per share, outstanding beginning Number of shares, granted Weighted average exercise price per share, granted Number of shares, exercised Weighted average exercise price per share, exercised Number of shares, cancelled or expired Weighted average exercise price per share, cancelled or expired Number of shares, outstanding beinning Weighted average exercise price per share, outstanding ending Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Total stock-based compensation Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Issued and sell, shares Offering price Warrants to purchase common stock Offering price Gross proceeds from offering Offering expenses payable issuance of warrants Stock issued for common stock Issuance of common stock, shares Exercise of stock option Warrants to purchase common stock expired unexercised Warrants outstanding Weighted average remaining contractual term of outstanding options Weighted average remaining contractual term of exercisable options Options were exercisable Weighted average exercise price, exercisable Intrinsic value of options, outstanding Intrinsic value of options, exercisable Fair Value, off-Balance-Sheet Risk [Table] Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items] Fair value recurring basis Total Balance, December 31, 2025 Fair value of warrants at issuance Change in fair value of warrants Balance, June 30, 2026 Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Subsidiary, Sale of Stock [Line Items] Exercise price Share price Expected life(Years) Expected life(Years) Expected volatility Risk-free interest rate Expected dividend yield Share price Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive securities  Segment Reporting [Table] Cash Cash equivalents Research and development studies Research and development materials Research and development costs Number of operating segment Number of reportable segments not disclosed flag Subsequent Event [Table] Subsequent Event [Line Items] Shares of common stock Warrant liability non current. Warrant issuance costs. Loss on issuance of warrants. Issuance of common stock shares and warrants in offering. Vesting of restricted common stock issued for services. Deferred offering costs included in accounts payable and accrued expenses. Offering costs in accounts payable and accrued expenses. Working capital Prepaid Expenses And Other Current Assets [Policy Text Block] Upfront payments for contractor fees, academic research studies and services, and subscriptions. Warrant Liability [Policy Text Block] New Accounting Pronouncements Not Yet Adopted Policy [Policy Text Block] License Strategic Alliance and Research Agreements [Member] Amount expensed for license strategic alliance and research agreements. Actuate Therapeutics [Member] Collaboration Agreement [Member] Number of hold shares. Reverse Stock Split and IPO [Member] Schedule of Balance Sheet Information Related to Leases [Table Text Block] Schedule of Reconciliation of Right-of-use Assets and Lease Liabilities [Table Text Block] Operating lease liability amortization expense Schedule of Other Supplemental Information Related to Operating Leases [Table Text Block] Share based compensation arrangement by share based payment award options exercised in period. Securities Purchase Agreement [Member] Pre-Funded Warrants [Member] Marketable Securities [Member] Manufacturing costs research and development studies. Manufacturing costs research and development materials. Open Medicine AI [Member] Placement Agent Warrants [Member] Schedule Of Change In Fair Value Warrant Liability [Table Text Block] Fair Value Of Warrants [Text Block] Schedule Of Assumptions Computing Fair Value Of Warrants [Table Text Block] Private Placement Warrants [Member] Schedule of Warrant Activity Fair Value Accounting [Table Text Block] Schedule of Warrants Issued and Outstanding [Table Text Block] Offering expenses payable. Board of Directors [Member] December 2025 [Member] April 2026 [Member] Placement Agent [Member] Fair value of warrants issued. Private Placement Warrants and Placement Agent Warrants [Member] Investors [Member] Single Operating Segment [Member] Number of reportable segments not disclosed flag. Lessee operating lease liabilites undiscounted excess amount. Assets, Current Assets Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Other Comprehensive Income (Loss), Net of Tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding VestingOfRestrictedCommonStockIssuedForServices Share-Based Payment Arrangement, Noncash Expense Investment Income, Net, Amortization of Discount and Premium Gain (Loss), Foreign Currency Transaction, before Tax Debt Securities, Available-for-Sale, Realized Gain (Loss) Unrealized Gain (Loss) on Investments Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Other Operating Assets Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Payments to Acquire Property, Plant, and Equipment Payments to Acquire Marketable Securities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Lessee, Leases [Policy Text Block] WorkingCapital Deferred Offering Costs [Default Label] Operating Lease, Liability Operating Lease, Right-of-Use Asset, Periodic Reduction OperatingLeaseLiabilityAmortizationExpense Lease, Cost Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period WarrantLiabilityNonCurrent Warrants and Rights Outstanding, Term Share Price